Drugs Of Abuse Panel-12 Drug Panel

Blood

Report in 48Hrs

At Home

No Fasting Required

Details

Rapid urine/blood screening panels.

₹7,696₹10,994

30% OFF

Drugs Of Abuse Panel-12 Drug Panel

Why is it done?
- Detects the presence of 12 commonly abused substances in urine or oral fluid samples to screen for drug use
- Typically includes screening for: Amphetamines, Methamphetamine, Cocaine, Marijuana (THC), Opioids (Morphine/Codeine), PCP, Benzodiazepines, Barbiturates, Methadone, MDMA (Ecstasy), Tricyclic Antidepressants, and Propoxyphene
- Used in workplace drug screening programs for employment compliance and occupational safety
- Performed during pre-employment evaluations, random workplace testing, post-incident investigations, and return-to-duty assessments
- Utilized in clinical settings to monitor compliance with prescribed medications and detect illicit drug use in patients
- May be ordered by law enforcement, legal proceedings, or as part of substance abuse treatment programs and rehabilitation monitoring
Normal Range
- Normal Result: NEGATIVE or NOT DETECTED for all 12 drug classes
- Cutoff Thresholds (screening level): Typically set at federally regulated levels (e.g., 300 ng/mL for cocaine, 50 ng/mL for amphetamines, 15 ng/mL for marijuana)
- Abnormal Result: POSITIVE or DETECTED - indicates substance levels above the established cutoff threshold
- Units of Measurement: Nanograms per milliliter (ng/mL) for immunoassay screening; various units for confirmatory testing (GC-MS)
- Borderline/Equivocal Results: Values near the cutoff threshold may require confirmatory testing using GC-MS (Gas Chromatography-Mass Spectrometry) to verify accuracy
- Invalid Result: Test cannot be interpreted due to sample issues (dilution, contamination, insufficient sample), requiring recollection
Interpretation
- Negative Result: Indicates no detectable levels of the 12 screened substances present in the sample at or above cutoff thresholds; suggests abstinence from these drugs
- Positive Result: Indicates detection of one or more substances above the established threshold; suggests recent use of the identified drug(s); does not differentiate between therapeutic use and illicit use
- Multiple Positive Results: Detection of multiple drugs suggests polysubstance use or potential cross-reactivity with certain medications or substances
- Factors Affecting Results:
  - Medication interference - certain prescribed medications (decongestants, antidepressants, pain relievers) may cause false positives
  - Timing of drug use - detection window varies by substance (THC: 2-30 days; cocaine: 2-4 days; opioids: 2-4 days; amphetamines: 2-3 days)
  - Passive exposure - secondhand smoke or vapors may result in minimal detection levels
  - Sample collection integrity - improper collection, dilution, or contamination affects validity
  - Cross-reactivity - poppy seeds or certain foods may trigger false positives for opioids
- Clinical Significance: Positive results require careful interpretation; confirmatory testing and clinical correlation with patient history are essential to distinguish legitimate medication use from illicit drug use and identify potential substance abuse disorders
Associated Organs
- Primary Organ Systems Involved:
  - Central Nervous System (CNS) - all abused substances affect neurotransmitter function and brain chemistry
  - Cardiovascular System - cocaine and amphetamines cause cardiac effects including arrhythmias and hypertension
  - Respiratory System - marijuana and cocaine smoking damages lungs; opioid use causes respiratory depression
  - Hepatic System - liver metabolizes most drugs; chronic use may cause liver damage
  - Renal System - kidneys filter and eliminate drug metabolites; chronic use may impair renal function
- Medical Conditions Associated with Abnormal Results:
  - Substance Use Disorder - diagnosed when drug use persists despite harmful consequences
  - Stimulant-induced Cardiovascular Events - myocardial infarction, stroke, arrhythmias from cocaine/amphetamine use
  - Opioid-induced Respiratory Depression - potentially fatal breathing suppression
  - Psychiatric Disorders - depression, anxiety, paranoia, psychosis associated with chronic drug use
  - Liver Disease - hepatitis from intravenous drug use; cirrhosis from prolonged alcohol combined with drug use
  - Infectious Diseases - HIV, Hepatitis B and C transmission through needle sharing
- Potential Complications of Drug Abuse:
  - Overdose and potential fatal respiratory depression or cardiac events
  - Withdrawal syndromes with potentially severe physiological effects
  - Cognitive impairment and long-term neurological damage
  - Organ toxicity affecting heart, lungs, liver, and kidneys
Follow-up Tests
- Confirmatory Testing (If Positive):
  - GC-MS (Gas Chromatography-Mass Spectrometry) - gold standard confirmatory test to verify screening results and differentiate between similar compounds
  - LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry) - alternative confirmatory method with high specificity
- Additional Diagnostic Tests (Based on Clinical Suspicion):
  - Blood Alcohol Level (BAC) - if alcohol use suspected alongside other drugs
  - Hepatitis Panel (A, B, C) - to screen for infections related to IV drug use
  - HIV Screening - recommended if IV drug use suspected
  - Liver Function Tests (AST, ALT, GGT) - assess hepatic damage from chronic drug use
  - Renal Function Panel (Creatinine, BUN) - evaluate kidney function compromised by drug use
  - Cardiac Assessment (ECG, Troponin) - for suspected stimulant use with cardiac symptoms
- Monitoring and Follow-up Testing:
  - Serial Drug Testing - periodic or random retesting in workplace programs or substance abuse treatment settings at intervals determined by employer or treatment provider
  - Comprehensive Metabolic Panel (CMP) - monitor overall health status during drug treatment and recovery
  - Drug Specific Toxicology Panels - targeted testing for specific substances based on treatment protocols
  - Hair Analysis Testing - provides extended detection window (up to 90 days) for monitoring long-term abstinence
- Complementary Assessments:
  - Psychological/Psychiatric Evaluation - assess for substance use disorder, co-occurring mental health conditions, and treatment needs
  - Addiction Medicine Consultation - specialized evaluation for substance abuse treatment planning and medication-assisted therapy options
Fasting Required?
- Fasting: NO - Fasting is not required for this test
- Sample Type: Urine (most common) or oral fluid/saliva specimen collected in sterile cup or collection device
- Timing Instructions:
  - Test can be performed at any time of day; first morning urine may provide more concentrated sample for better detection
- Medications to Report (Not necessarily to avoid):
  - Inform healthcare provider of all medications, supplements, and herbal remedies, as certain prescription and over-the-counter medications may cause false positive results
  - Common medications that may cause false positives: Decongestants/pseudoephedrine (amphetamines), Dextromethorphan cough suppressants (PCP), Certain antidepressants (tricyclic compounds), NSAIDs and ibuprofen (potential interference)
- Patient Preparation:
  - No specific preparation needed; can eat and drink normally before test
  - Void urine before collection to provide fresh sample, then collect midstream urine in provided sterile container
  - For observed collections (workplace/legal testing): Privacy provided while maintaining chain of custody protocols; may involve bathroom observation
  - Remove excess clothing for collection to prevent sample tampering
  - Ensure sample collection occurs within specified time frame of testing requirement

How our test process works!